IntuitionLabs"If regulatory submissions proceed in 2026 and receive FDA priority review, approval could occur in late 2026 or early 2027. "Jul 16, 2026
Clinical Trial Vanguard"The first FDA approval of an AI-discovered drug, projected for sometime in 2026 or 2027, will be treated as a validation event for the entire sector."Aug 27, 2026
Healthcare Discovery"First, no AI-discovered drug has yet reached FDA approval, and the first approval, most likely from the Insilico IPF program or one of the Recursion oncology assets, is unlikely before 2028."May 16, 2026
Cambridge Healthtech Institute"Insilico sketched out a timeline that included first patient enrolled by September 2025, last patient enrolled by November 2028, with initial results expected by December 2029, a potential NDA by March 2030 and approval by September 2030."Sep 23, 2026
OncoDaily"The more precise version, drawn from industry analyses such as IntuitionLabs’ review of the AI drug pipeline, is that the first FDA approval of any AI-discovered drug is projected for 2026–2027."Jun 30, 2026
aidrugsearch"Based on current Phase III trial progress and regulatory adaptation, the first fully AI-discovered drug could receive FDA approval between 2028 and 2030."Aug 24, 2026
BioSpectrum Asia"Significantly, the rate of change appears to be accelerating, with 62% forecasting that the first fully AI drug discovered and developed therapy will be approved by the FDA within the next 5 years – with 20% believing this can be achieved in under 2-years"Sep 23, 2026